retatrutide triple hormone receptor agonist benefits The power of three: Retatrutide's role in modern obesity and diabetes therapy Triple–Hormone-Receptor Agonist Retatrutide for Obesity

One major reason for excitement around retatrutide for weight loss is the strong clinical trial data showing substantial body weight reduction

Earlier research and case reports also suggest a significant rise in NAION cases among patients treated with semaglutide and tirzepatide, with some reports indicating up to a fourfold increase in risk

Dulaglutide and cardiovascular outcomes in type 2 diabetes (Rewind): a double-blind, randomised placebo-controlled trial

Efficacy and safety of once-weekly semaglutide versus once-daily Sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (sustain 2): a 56-week, double-blind, phase 3a, randomised trial